Brokerages Anticipate Conatus Pharmaceuticals Inc (CNAT) Will Announce Earnings of -$0.13 Per Share
Equities research analysts expect Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to announce ($0.13) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from ($0.20) to ($0.02). Conatus Pharmaceuticals also reported earnings of ($0.13) per share in the same quarter last year. The company is expected to report its next quarterly earnings report on Wednesday, November 7th.
Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Conatus Pharmaceuticals had a negative return on equity of 69.68% and a negative net margin of 48.46%. The firm had revenue of $8.77 million for the quarter, compared to analysts’ expectations of $9.06 million.
Shares of Conatus Pharmaceuticals stock traded up $0.79 during trading on Monday, reaching $5.20. 1,516,571 shares of the stock were exchanged, compared to its average volume of 184,470. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.68. The firm has a market cap of $124.50 million, a P/E ratio of -8.52 and a beta of 1.23. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95.
Several institutional investors have recently bought and sold shares of CNAT. The Manufacturers Life Insurance Company boosted its holdings in shares of Conatus Pharmaceuticals by 253.0% during the first quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 16,476 shares during the period. Jane Street Group LLC purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter worth about $142,000. MYDA Advisors LLC purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter worth about $154,000. Wells Fargo & Company MN boosted its holdings in shares of Conatus Pharmaceuticals by 77.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,036 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 14,848 shares during the period. Finally, LMR Partners LLP purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter worth about $311,000. Institutional investors own 34.93% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Story: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.